UGP2 Antibody

What is UGP2 and what is its significance in cellular metabolism?

UDP-glucose pyrophosphorylase 2 (UGP2) is an important intermediary enzyme in mammalian carbohydrate interconversions. It catalyzes the transfer of a glucose moiety from glucose-1-phosphate to MgUTP, resulting in the formation of UDP-glucose and MgPPi . UGP2 functions as a lynchpin metabolic enzyme at the convergence of multiple pathways that regulate both glycogen synthesis and glycosylation modifications .

In liver and muscle tissue, UDP-glucose serves as a direct precursor for glycogen synthesis, while in lactating mammary gland it is utilized differently . The enzyme's critical role in carbohydrate metabolism makes it essential for normal cellular function across various tissues.

What are the known isoforms of UGP2 and their tissue distribution?

UGP2 exists in at least two significant isoforms with distinct tissue distributions:

• A longer isoform: Found in various tissues

• A shorter isoform: Predominant in the brain

Research has demonstrated that disruption of the start codon of the shorter isoform (through mutations) leads to a reduction of functional UGP2 enzyme in neural stem cells. This reduction results in altered glycogen metabolism, upregulated unfolded protein response, and premature neuronal differentiation . The complete absence of all UGP2 isoforms leads to differentiation defects across multiple lineages in human cells, indicating its fundamental importance in development.

What are the optimal applications for UGP2 antibody detection?

Based on validated research applications, UGP2 antibodies can be effectively utilized in several experimental techniques:

For immunohistochemistry applications, antigen retrieval methods impact results significantly. Research indicates that TE buffer pH 9.0 is suggested for optimal antigen retrieval, though citrate buffer pH 6.0 may be used as an alternative .

How can researchers validate the specificity of UGP2 antibodies in experimental systems?

Robust validation of UGP2 antibody specificity requires multiple approaches:

• Genetic validation: Testing in UGP2 knockout models is the gold standard. Research has employed CRISPR/Cas9 genome editing to generate knockout clones with a single nucleotide insertion at position 42 of UGP2 transcript 1, leading to an out-of-frame transcript and premature termination of the protein . Western blotting can confirm the absence of all UGP2 protein in knockout clones.

• Isoform specificity: For isoform-specific studies, validation should demonstrate differential detection of the long versus short isoforms. The absence of the short UGP2 isoform in cells with the patient mutation provides a useful control .

• Molecular weight verification: UGP2 has a calculated molecular weight of 56 kDa, though observed molecular weight typically ranges from 50-56 kDa in Western blot applications .

• Cross-reactivity assessment: Testing across multiple species when needed, with verified reactivity in human, mouse, and rat samples being most common .

What factors should be considered when selecting a UGP2 antibody for cancer research?

When selecting UGP2 antibodies specifically for cancer research:

• Epitope selection: Consider antibodies targeting different regions of UGP2 (N-terminal, C-terminal, or internal domains). Available commercial antibodies include those targeting amino acids 1-90, 1-508, 1-497, 467-497 (C-terminal), and 40-89 .

• Validated cancer tissues: Select antibodies with demonstrated efficacy in relevant cancer tissues. Published research shows UGP2 antibody validation in human ovary tumor tissue, human liver cancer tissue, and breast cancer tissue .

• Application compatibility: Ensure the antibody is validated for your specific application in cancer research. For instance, IHC applications are critical for evaluating UGP2 expression in tumor samples, while WB might be more relevant for cell line studies.

• Publication record: Consider antibodies with published use in cancer research contexts. Several UGP2 antibodies have been cited in publications involving knockdown/knockout studies and cancer-related investigations .

What is the role of UGP2 in cancer progression and how can antibodies help elucidate mechanisms?

UGP2 has emerged as a critical factor in cancer biology, particularly in pancreatic cancer. Research reveals that:

UGP2 expression correlates strongly with poor prognosis in pancreatic ductal adenocarcinoma (PDAC) tumors, particularly in early phase and low-grade tumors . This significant correlation suggests its potential utility as a biomarker.

Mechanistically, UGP2 functions as a critical regulator of protein glycosylation in pancreatic cancer . The YAP/TEAD transcription factor complex has been identified as a major regulator of UGP2 mRNA expression and enzymatic activity. This connection is especially relevant since YAP is a key effector of KRAS oncogenic function .

Functional studies using UGP2 antibodies have demonstrated that loss of UGP2 leads to:

• Decreased glycogen production

• Defects in key glycosylation targets such as EGFR

• Prevention of tumor growth in murine xenograft models using pancreatic cancer lines

These findings suggest UGP2 is essential for maintaining KRAS-driven cancers, potentially opening new therapeutic avenues in otherwise difficult-to-treat malignancies.

How is UGP2 implicated in neurological disorders?

Research has uncovered an important role for UGP2 in neurological development and function:

A recurrent start codon mutation in UGP2 has been identified as the cause of a novel autosomal recessive developmental epileptic encephalopathy (DEE) syndrome . This mutation creates a tolerable Met12Val missense change in the longer UGP2 isoform but critically disrupts the start codon of the shorter isoform that predominates in the brain.

The functional consequence of this mutation was demonstrated through cellular models showing:

• Reduction of functional UGP2 enzyme in neural stem cells

• Altered glycogen metabolism

• Upregulated unfolded protein response

• Premature neuronal differentiation

Animal models further support UGP2's neurological importance, as reduced expression of Ugp2a/Ugp2b in zebrafish mimics visual disturbance and results in behavioral phenotypes .

How can UGP2 antibodies be utilized in glycosylation pathway research?

UGP2 antibodies provide valuable tools for investigating glycosylation pathways:

• Target protein glycosylation analysis: Research shows that loss of UGP2 leads to defects in key glycosylation targets such as EGFR . UGP2 antibodies can be used in co-immunoprecipitation studies to identify protein complexes involved in glycosylation regulation.

• Metabolic pathway mapping: By combining UGP2 antibody detection with metabolomic approaches, researchers can correlate UGP2 protein levels with UDP-glucose production and subsequent glycosylation patterns.

• Cancer glycosylation mechanisms: UGP2 has been identified as a critical regulator of protein glycosylation in pancreatic cancer . Antibodies can help track changes in UGP2 expression across different stages of cancer progression to understand glycosylation's role in malignancy.

• Therapeutic target validation: In knockout/knockdown validation studies, UGP2 antibodies serve as essential tools to confirm protein reduction and correlate with phenotypic outcomes in glycosylation-dependent processes .

What strategies should be employed when investigating isoform-specific functions of UGP2?

To investigate isoform-specific functions of UGP2:

• Isoform-specific detection: Select antibodies capable of distinguishing between the longer and shorter UGP2 isoforms. Western blotting can confirm "the absence of all UGP2 proteins in knockout clones and the loss of the short UGP2 isoform in clones with the patient mutation" .

• Genetic manipulation approaches: Researchers have successfully employed site-directed mutagenesis to disrupt the start codon of the shorter UGP2 isoform while maintaining expression of the longer isoform. This approach mimics the natural mutation found in patients with epileptic encephalopathy .

• Rescue experiments: As demonstrated in published research, engineering stable cell lines expressing either wild-type or mutant UGP2 isoforms can determine isoform-specific functions. Cells with the transgene integration can be selected with puromycin to ensure stable expression .

• Differential tissue analysis: Given that the shorter isoform predominates in brain tissue, comparative analysis of UGP2 expression and function across neural and non-neural tissues can provide insights into isoform-specific roles.

What are common challenges when using UGP2 antibodies in immunohistochemistry?

When using UGP2 antibodies for immunohistochemistry, researchers should address these common challenges:

How can researchers optimize Western blot protocols for challenging UGP2 detection scenarios?

For optimal UGP2 detection by Western blotting in challenging scenarios: